Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis. (Q37000514)
Jump to navigation
Jump to search
scientific article published on 16 May 2013
Language | Label | Description | Also known as |
---|---|---|---|
English | Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis. |
scientific article published on 16 May 2013 |
Statements
Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis (English)
Soo Ok Lee
Yuanjie Niu
Defeng Xu
Liang Liang
Lei Li
Shauh-Der Yeh
Naohiro Fujimoto
Shuyuan Yeh
1 reference
1 reference
1 reference